The blood cells in NSCLC and the changes after RFA

References

• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA A Cancer J Clin. 2020;70(1):7–30.
   PubMed Web of Science ®Google Scholar
• Feng RM, Zong YN, Cao SM, et al. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? Cancer Commun (Lond)). 2019;39(1):22.
   PubMed Web of Science ®Google Scholar
• Schnabel PA, Junker K. Pulmonary neuroendocrine tumors in the new WHO 2015 classification: start of breaking new grounds? Pathologe. 2015;36(3):283–292.
   PubMed Web of Science ®Google Scholar
• Poggi A, Zocchi MR. Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells. Arch Immunol Ther Exp (Warsz). 2006;54(5):323–333.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.
   PubMed Web of Science ®Google Scholar
• Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy[J]. Nat Rev Cancer. 2014;14(3):199–208.
   PubMed Web of Science ®Google Scholar
• LeVeen HH, Wapnick S, Piccone V, et al. Tumor eradication by radiofrequency therapy. Responses in 21 patients. JAMA. 1976;235(20):2198–2200.
   PubMed Web of Science ®Google Scholar
• Sugaar S, LeVeen HH. A histopathologic study on the effects of radiofrequency thermotherapy on malignant tumors of the lung. Cancer. 1979;43(2):767–783.
   PubMed Web of Science ®Google Scholar
• Goldberg SN, Gazelle GS, Compton CC, et al. Radiofrequency tissue ablation in the rabbit lung: efficacy and complications. Acad Radiol. 1995;2(9):776–784.
   PubMed Web of Science ®Google Scholar
• Dupuy DE, Zagoria RJ, Akerley W, et al. Percutaneous radiofrequency ablation of malignancies in the lung. AJR Am J Roentgenol. 2000;174(1):57–59.
   PubMed Web of Science ®Google Scholar
• Cheng QS, Zhao ZY, Liu K, et al. Percutaneous radiofrequency hyperthermia for lung cancer by the using of computer tomography-guided anchor-shaped electrode report of 105 cases[J]. J Fourth Mil Med Univ. 2000; 21(11):1399–1401.
   Google Scholar
• Mrowiet ZU. Advances in systemic therapy for psoriasis. Clin Exp Dermatol. 2001;26(4):362–367.
   PubMed Web of Science ®Google Scholar
• Nikfarjam M, Muralidharan V, Christophi C. Mechanisms of focal heat destruction of liver tumors. J. Surg. Res. 2005;127(2):208–223.
   PubMed Web of Science ®Google Scholar
• Slovak R, Ludwig JM, Gettinger SN, et al. Immuno-thermal ablations – boosting the anticancer immune response. J Immunother Cancer. 2017;5(1):78.
   PubMed Web of Science ®Google Scholar
• Fagnoni FF, Zerbini A, Pelosi G, et al. Combination of radiofrequency ablation and immunotherapy. Front Biosci. 2008;13:369–381.
   PubMed Web of Science ®Google Scholar
• Schneider T, Hoffmann H, Dienemann H, et al. Immune response after radiofrequency ablation and surgical resection in nonsmall cell lung cancer[J]. Semin Thorac Cardiovasc Surg. 2016;28(2):585–592.
   PubMed Web of Science ®Google Scholar
• Deng Z, Zhang W, Han Y, et al. Radiofrequency ablation inhibits lung metastasis of breast cancer in mice. Zhonghua Zhong Liu Za Zhi. 2015;37(7):497–500.
   PubMedGoogle Scholar
• Clasen S, Krober SM, Kosan B, et al. Pathomorphologic evaluation of pulmonary radiofrequency ablation: proof of cell death is characterized by DNA fragmentation and apoptotic bodies. Cancer. 2008;113(11):3121–3129.
   PubMed Web of Science ®Google Scholar
• Pereira PL. Actual role of radiofrequency ablation of liver metastases. Eur Radiol. 2007;17(8):2062–2070.
   PubMed Web of Science ®Google Scholar
• Fajardo LF, Egbert B, Marmor J, et al. Effects of hyperthermia in a malignant tumor. Cancer. 1980;45(3):613–623.
   PubMed Web of Science ®Google Scholar
• Siegel I, Lin Liu T, Gleicher N. The red-cell immune system. Lancet. 1981;318(8246):556–559.
   Google Scholar
• Anderson HL, Brodsky IE, Mangalmurti NS. The evolving erythrocyte: red blood cells as modulators of innate immunity. J Immunol. 2018;201(5):1343–1351.
   PubMed Web of Science ®Google Scholar
• Ding Y, Guo H, Gu WJ. Progress of erythrocyte immunity in tumor research. J Liaoning Uni TCM. 2007;9(1):68–69.
   Google Scholar
• Ng T, Ryder BA, Chern H, et al. Leukocyte-depleted blood transfusion is associated with decreased survival in resected early-stage lung cancer. J Thorac Cardiovasc Surg. 2012;143(4):815–819.
   PubMed Web of Science ®Google Scholar
• Genova C, Rijavec E, Barletta G, et al. Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer. Expert Opin Biol Ther. 2012;12(7):939–948.
   PubMed Web of Science ®Google Scholar
• Wan H, Zeng X, Yu J, et al. Red-cell immune functions, T subsets and B-cell detection and their clinical significances in patients with primary lung cancer. Zhongguo Fei Ai Za Zhi. 2001;4(5):351–353.
   PubMedGoogle Scholar
• Zhang WQ, Suo XH, Lin H. the effects on immune function of patients with non-small cell lung cancer after hyperthermia radiofrenquency ablation. Chin Gen Pract. 2002;5(3):197–198.
   Google Scholar
• Aulakh GK. Neutrophils in the lung: “the first responders”. Cell Tissue Res. 2018;371(3):577–588.
   PubMed Web of Science ®Google Scholar
• Nicolás-Ávila JÁ, Adrover JM, Hidalgo A. Neutrophils in homeostasis, immunity, and cancer. Immunity. 2017;46(1):15–28.
   PubMed Web of Science ®Google Scholar
• Fridlender ZG, Sun J, Kim S, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell. 2009;16(3):183–194.
   PubMed Web of Science ®Google Scholar
• Eruslanov EB, Bhojnagarwala PS, Quatromoni JG, et al. Tumor associated neutrophils stimulate T cell responses in early-stage human lung cancer. J Clin Invest. 2014;124(12):5466–5480.
   PubMed Web of Science ®Google Scholar
• Singhal S, Bhojnagarwala PS, O'Brien S, et al. Origin and role of a subset of tumor-associated neutrophils with antigen-presenting cell features in early-stage human lung cancer. Cancer Cell. 2016;30(1):120–135.
   PubMed Web of Science ®Google Scholar
• Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med. 2011;17(11):1359–1370.
   PubMed Web of Science ®Google Scholar
• Di Carlo E, Forni G, Lollini P, et al. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood. 2001;97(2):339–345.
   PubMed Web of Science ®Google Scholar
• Jakóbisiak M, Lasek W, Gołąb J. Natural mechanisms protecting against cancer. Immunol Lett. 2003;90(2-3):103–122.
   PubMed Web of Science ®Google Scholar
• Engblom C, Pfirschke C, Zilionis R, et al. Osteoblasts remotely supply lung tumors with cancer-promoting SiglecFhigh neutrophils. Science. 2017;358(6367):eaal5081.
   PubMed Web of Science ®Google Scholar
• Kowanetz M, Wu XM, Lee J, et al. Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G + Ly6C + granulocytes. Proc Natl Acad Sci USA. 2010;107(50):21248–21255.
   PubMed Web of Science ®Google Scholar
• Dumitru CA, Fechner MK, Hoffmann TK, et al. A novel p38-MAPK signaling axis modulates neutrophil biology in head and neck cancer. J Leukoc Biol. 2012;91(4):591–598.
   PubMed Web of Science ®Google Scholar
• Vaguliene N, Zemaitis M, Lavinskiene S, et al. Local and systemic neutrophilic inflammation in patients with lung cancer and chronic obstructive pulmonary disease. BMC Immunol. 2013; 14(1):1–11.
   PubMed Web of Science ®Google Scholar
• Radvanyi LG. Tumor-infiltrating lymphocyte therapy: addressing prevailing questions. Cancer J. 2015;21(6):450–464.
   PubMed Web of Science ®Google Scholar
• Song QK, Ren J, Zhou XN, et al. The prognostic value of peripheral CD4 + CD25+ T lymphocytes among early stage and triple negative breast cancer patients receiving dentritic cellscytokine induced killer cells infusion. Oncotarget. 2015;6(38):41350–41359.
   PubMedGoogle Scholar
• Donnem T, Hald SM, Paulsen EE, et al. Stromal CD8+ T-cell density – a promising supplement to TNM staging in non-small cell lung cancer. Clin Cancer Res. 2015;21(11):2635–2643.
   PubMed Web of Science ®Google Scholar
• Al-Shibli KI, Donnem T, Al-Saad S, et al. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res. 2008;14(16):5220–5227.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pagès F, Sautès-Fridman C, et al. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298–306.
   PubMed Web of Science ®Google Scholar
• Zhu JF, Paul WE. CD4 T cells: fates, functions, and faults. Blood. 2008;112(5):1557–1569.
   PubMed Web of Science ®Google Scholar
• Ivanova EA, Orekhov AN. T helper lymphocyte subsets and plasticity in autoimmunity and cancer: an overview. Biomed Res Int. 2015; 2015:327470.
   PubMed Web of Science ®Google Scholar
• Gasper DJ, Tejera MM, Suresh M. CD4 T-cell memory generation and maintenance. Crit Rev Immunol. 2014;34(2):121–146.
   PubMed Web of Science ®Google Scholar
• Boost KA, Sadik CD, Bachmann M, et al. IFN-gamma impairs release of IL-8 by IL-1beta-stimulated A549 lung carcinoma cells. BMC Cancer. 2008;(8):265.
   PubMed Web of Science ®Google Scholar
• Nguyen AH, Berim IG, Agrawal DK. Cellular and molecular immunology of lung cancer: therapeutic implications. Expert Rev Clin Immunol. 2014;10(12):1711–1730.
   PubMed Web of Science ®Google Scholar
• Vahl JM, Friedrich J, Mittler S, et al. Interleukin-10-regulated tumour tolerance in non-small cell lung cancer. Br J Cancer. 2017;117(11):1644–1655.
   PubMed Web of Science ®Google Scholar
• Domagala-Kulawik J, Osinska I, Hoser G. Mechanisms of immune response regulation in lung cancer. Transl Lung Cancer Res. 2014;3(1):15–22.
   PubMedGoogle Scholar
• Li J, Wang Z, Mao K, et al. Clinical significance of serum T helper 1/T helper 2 cytokine shift in patients with non-small cell lung cancer. Oncol Lett. 2014;8(4):1682–1686.
   PubMed Web of Science ®Google Scholar
• Pan B, Shen J, Cao J, et al. Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3/GIV signaling pathway in non-small-cell lung cancer. Sci Rep. 2015;(5):16053.
   PubMed Web of Science ®Google Scholar
• Gu K, Li MM, Shen J, et al. Interhukin-17-induced EMT promotes lung cancer cell migration and invasion via NF-κB/ZEBl signal pathway. Am J Cancer Res. 2015;5(3):1169–1179.
   PubMed Web of Science ®Google Scholar
• Hanagiri T, Fukumoto M, Koyanagi Y, et al. Regulatory T-cells and micrometastasis in lymph nodes of stage I NSCLC. Anticancer Res. 2014;34(12):7185–7190.
   PubMed Web of Science ®Google Scholar
• Duan MC, Zhong XN, Liu GN, et al. The Treg/Th17 paradigm in lung cancer. J Immunol Res. 2014;2014:730380.
   PubMed Web of Science ®Google Scholar
• Bold TD, Ernst JD. CD4+ T cell-dependent IFN-γ production by CD8+ effector T cells in Mycobacterium tuberculosis infection. J Immunol. 2012;189(5):2530–2536.
   PubMed Web of Science ®Google Scholar
• Shaobin W, Yu X, Jiatian L, et al. Changes of CD4(+) T-cell subsets after radiofrequency ablation in lung cancer and its significance. J Can Res Ther. 2016;12(7):166–170.
   Web of Science ®Google Scholar
• Higgins JP, Bernstein MB, Hodge JW. Enhancing immune responses to tumor-associated antigens[J]. Cancer Biol Ther. 2009;8(15):1440–1449.
   PubMed Web of Science ®Google Scholar
• Kudo M. Immuno-oncology in hepatocellular carcinoma: 2017 Update. Oncology. 2017;93(1):147–159.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Hellwig B, Hammad S, et al. A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors. Clin Cancer Res. 2012;18(9):2695–2703.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Böhm D, von TC, et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 2008; 68(13):5405–5413.
   PubMed Web of Science ®Google Scholar
• Biragyn A, Lee-Chang C. A new paradigm for an old story: the role of regulatory B cells in cancer. Front Immunol. 2012;3:206.
   PubMed Web of Science ®Google Scholar
• Saze Z, Schuler PJ, Hong CS, et al. Adenosine production by human B cells and B cell-mediated suppression of activated T cells. Blood. 2013;122(1):9–18.
   PubMed Web of Science ®Google Scholar
• Ding ZH, Jiang L, Zhang K, et al. Study on the effect of LRFA under ultrasound guidance in immune function of patients with advanced hepatocellular carcinoma. J Clin Exp Med. 2017;16(15):44–47.
   Google Scholar
• Wu J, Lanier LL. Natural killer cells and cancer. Adv Cancer Res. 2003;90:127–156.
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Hayakawa Y, Takeda K, et al. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer. 2002;2(11):850–861.
   PubMed Web of Science ®Google Scholar
• Hayakawa Y, Huntington ND, Nutt SL, et al. Functional subsets of mouse natural killer cells. Immunol Rev. 2006;214:47–55.
   PubMed Web of Science ®Google Scholar
• Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008;9(5):495–502.
   PubMed Web of Science ®Google Scholar
• Carrega P, Morandi B, Costa R, et al. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer. 2008;112(4):863–875.
   PubMed Web of Science ®Google Scholar
• Gotthardt D, Putz EM, Grundschober E, et al. STAT5 is a key regulator in NK cells and acts as a molecular switch from tumor surveillance to tumor promotion. Cancer Discov. 2016;6(4):414–429.
   PubMed Web of Science ®Google Scholar
• Lavin Y, Kobayashi S, Leader A, et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell. 2017;169(4):750–765.
   PubMed Web of Science ®Google Scholar
• Pasero C, Gravis G, Guerin M, et al. Inherent and tumor-driven immune tolerance in the prostate microenvironment impairs natural killer cell antitumor activity. Cancer Res. 2016;76(8):2153–2165.
   PubMed Web of Science ®Google Scholar
• Mo Z, Lu H, Mo S, et al. Ultrasound-guided radiofrequency ablation enhances natural killer-mediated antitumor immunity against liver cancer. Oncol Lett. 2018;15(5):7014–7020.
   PubMed Web of Science ®Google Scholar
• Gunther S, Ostheimer C, Stangl S, et al. Correlation of Hsp70 serum levels with gross tumor volume and composition of lymphocyte subpopulations in patients with squamous cell and adeno non-small cell lung cancer. Front Immunol. 2015;6:556.
   PubMed Web of Science ®Google Scholar
• Dayanc BE, Beachy SH, Ostberg JR, et al. Dissecting the role of hyperthermia in natural killer cell mediated anti-tumor responses. Int J Hyperthermia. 2008;24(1):41–56.
   PubMed Web of Science ®Google Scholar
• Bonecchi R, Locati M, Mantovani A. Chemokines and cancer: a fatal attraction. Cancer Cell. 2011;19(4):434–435.
   PubMed Web of Science ®Google Scholar
• Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66(2):605–612.
   PubMed Web of Science ®Google Scholar
• Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3(1):23–35.
   PubMed Web of Science ®Google Scholar
• Coffelt SB, Hughes R, Lewis CE. Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta. 2009;1796(1):11–18.
   PubMed Web of Science ®Google Scholar
• Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39–51.
   PubMed Web of Science ®Google Scholar
• Guo DH, Mao ZP, Wang DY, et al. Regulation of radiofrequency ablation on polarization of type M2 macrophages in hepatic tissue of rats. J Xinxiang Med Uni. 2018;35(10):849–853.
   Google Scholar
• Sorrentino R, Morello S, Luciano A, et al. Plasmacytoid dendritic cells alter the antitumor activity of CpG-oligodeoxynucleotides in a mouse model of lung carcinoma. JI. 2010;185(8):4641–4650.
   Google Scholar
• Zhou Y, McEarchern JA, Howard E, et al. Dendritic cells efficiently acquire and present antigen derived from lung cancer cells and induce antigen-specific T-cell responses. Cancer Immunol Immunother. 2003;52(7):413–422.
   PubMed Web of Science ®Google Scholar
• Gunzer M, Varga G, Grabbe S, et al. Dendritic cells and tumor immunity. Semin Immunol. 2001;13(5):291–302.
   PubMed Web of Science ®Google Scholar
• Merad M, Sathe P, Helft J, et al. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol. 2013;31:563–604.
   PubMed Web of Science ®Google Scholar
• Whiteside TL, Odoux C. Dendritic cell biology and cancer therapy. Cancer Immunol Immunother. 2004;53(3):240–248.
   PubMed Web of Science ®Google Scholar
• Adam C, King S, Allgeier T, et al. DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction. Blood. 2005;106(1):338–344.
   PubMed Web of Science ®Google Scholar
• Herman S, Krenbek D, Klimas M, et al. Regulatory T cells form stable and long-lasting cell cluster with myeloid dendritic cells (DC). Int Immunol. 2012;24(7):417–426.
   PubMed Web of Science ®Google Scholar
• Kassner N, Krueger M, Yagita H, et al. Cutting edge: plasmacytoid dendritic cells induce IL-10 production in T cells via the Delta-like-4/Notch axis. J Immunol. 2010;184(2):550–554.
   PubMed Web of Science ®Google Scholar
• Yang GX, Lian ZX, Kikuchi K, et al. CD4- plasmacytoid dendritic cells (pDCs) migrate in lymph nodes by CpG inoculation and represent a potent functional subset of pDCs. J Immunol. 2005;174(6):3197–3203.
   PubMed Web of Science ®Google Scholar
• Xu A, Zhang L, Yuan J, et al. TLR9 agonist enhances radiofrequency ablation-induced CTL responses, leading to the potent inhibition of primary tumor growth and lung metastasis. Cell Mol Immunol. 2019;16(10):820–832.
   PubMed Web of Science ®Google Scholar
• Hogan SP, Rosenberg HF, Moqbel R, et al. Eosinophils: biological properties and role in health and disease. Clin Exp Allergy. 2008;38(5):709–750.
   PubMed Web of Science ®Google Scholar
• Caruso RA, Parisi A, Quattrocchi E, et al. Ultrastructural descriptions of heterotypic aggregation between eosinophils and tumor cells in human gastric carcinomas. Ultrastruct Pathol. 2011;35(4):145–149.
   PubMed Web of Science ®Google Scholar
• Lee JJ, Jacobsen EA, McGarry MP, et al. Eosinophils in health and disease: the LIAR hypothesis. Clin Exp Allergy. 2010;40(4):563–575.
   PubMed Web of Science ®Google Scholar
• Furbert-Harris PM, Hunter KA, VauIghn TR, et al. Eosinophils in a tri-cell multi-cellular tumor spheroid(MTS)/endothelium complex. Cell Mol Biol. 2003;49(7):1081–1088.
   PubMed Web of Science ®Google Scholar
• Furbert-Harris PM, Parish-Gause D, Hunter KA, et al. Activated eosinophils upregulate the metastasis suppressor molecule E-cadherin on prostate tumor cells. Cell. Mol. Biol. (Noisy-le-Grand). 2003;49(7):1009–1016.
   PubMed Web of Science ®Google Scholar
• Sakkal S, Miller S, Apostolopoulos V, et al. Eosinophils in cancer: favourable or unfavourable?. Curr Med Chem. 2016;23(7):650–666.
   PubMed Web of Science ®Google Scholar
• Benatar T, Cao MY, Lee Y, et al. IL-17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo. Cancer Immunol Immunother. 2010;59(6):805–817.
   PubMed Web of Science ®Google Scholar
• Gatault S, Legrand F, Delbeke M, et al. Involvement of eosinophils in the anti-tumor response. Cancer Immunol Immunother. 2012;61(9):1527–1534.
   PubMed Web of Science ®Google Scholar
• Takada K, Shimokawa M, Tanaka K, et al. Association between peripheral blood markers and immune-related factors on tumor cells in patients with resected primary lung adenocarcinoma. PLoS One. 2019;14(6):e0217991. Published 2019 Jun 4.
   PubMed Web of Science ®Google Scholar
• Samoszuk M. Eosinophils and human cancer. Histol Histopathol. 1997;12(3):807–812.
   PubMed Web of Science ®Google Scholar
• Anthony HM. Blood basophils in lung cancer. Br J Cancer. 1982;45(2):209–216.
   PubMed Web of Science ®Google Scholar
• Zenan H, Zixiong L, Zhicheng Y, et al. Clinical prognostic evaluation of immunocytes in different molecular subtypes of breast cancer. J Cell Physiol. 2019;234(11):20584–20602.
   PubMed Web of Science ®Google Scholar
• Stegner D, Dütting S, Nieswandt B. Mechanistic explanation for platelet contribution to cancer metastasis. Thromb Res. 2014;133(Suppl 2):S149–S157.
   PubMed Web of Science ®Google Scholar
• Jurasz P, Alonso-Escolano D, Radomski MW. Platelet-cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol. 2004;143(7):819–826.
   PubMed Web of Science ®Google Scholar
• Sadallah S, Schmied L, Eken C, et al. Platelet-derived ectosomes reduce NK cell function. J Immunol. 2016;197(5):1663–1671.
   PubMed Web of Science ®Google Scholar
• Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6)dju124.
   PubMedGoogle Scholar
• Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20(5):576–590.
   PubMed Web of Science ®Google Scholar
• Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost. 2011;9(2):237–249.
   PubMed Web of Science ®Google Scholar
• Menter DG, Tucker SC, Kopetz S, et al. Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Rev. 2014;33(1):231–269.
   PubMed Web of Science ®Google Scholar
• Ho-Tin-Noé B, Goerge T, Wagner DD. Platelets: guardians of tumor vasculature. Cancer Res. 2009;69(14):5623–5626.
   PubMed Web of Science ®Google Scholar
• Tomita M, Shimizu T, Ayabe T, et al. Prognostic significance of the combined use of preoperative platelet count and serum carcinoembryonic antigen level in non-small-cell lung cancer. Gen Thorac Cardiovasc Surg. 2010;58(11):573–576.
   PubMedGoogle Scholar
• Mazmishvili K, Jayant K, Janikashvili N, et al. Study to evaluate the immunomodulatory effects of radiofrequency ablation compared to surgical resection for liver cancer. J Cancer. 2018;9(17):3187–3195.
   PubMed Web of Science ®Google Scholar